|
1) Macdougall IC, Gray SJ, Elston O, et al. Pharmacokinetics of novel erythropoiesis stimulating protein compared with epoetin alfa in dialysis patients. J Am Soc Nephrol. 1999; 10: 2392-5
|
|
|
|
2) Vanrenterghem Y, Barany P, Mann JF, et al. Randomized trial of darbepoetin alfa for treatment of renal anemia at a reduced dose frequency compared with rHuEPO in dialysis patients. Kidney Int. 2002; 62: 2167-75
|
|
|
|
|
3) Nissenson AR, Swan SK, Lindberg JS, et al. Randomized controlled trial of darbepoetin alfa for the treatment of anemia in hemodialysis patients. Am J Kidney Dis. 2002; 40: 110-8
|
|
|
|
|
|
4) Osterborg A, Hellmann A, Steegmann JL, et al. C. E. R. A. (Continuous Erythropoiesis Receptor Activator): dose-response trial of subcutaneous (SC) administration once every 3 weeks (Q3W) to patients with aggressive non-Hodgkin's lymphoma and anemia receiving chemotherapy (abstract). Blood. 2004; 104: 142b, 4225
|
|
|
|
|
|
5) Sulowicz W, Locatelli F, Ryckelynck JP, et al. Once-monthly subcutaneous C. E. R. A. maintains stable hemoglobin control in patients with chronic kidney disease on dialysis and converted directly from epoetin one to three times weekly. Clin J Am Soc Nephrol. 2007; 2: 637-46
|
|
|
|
|
|
6) Osterborg A, Steegmann JL, Hellmann A, et al. Phase II study of three dose levels of continuous erythropoietin receptor activator (C. E. R. A. ) in anaemic patients with aggressive non-Hodgkin's lymphoma receiving combination chemotherapy. Br J Haematol. 2007; 136: 736-44
|
|
|
|
|
|
7) Dmoszynska A, Kloczko J, Rokicka M, et al. A dose exploration, phase I/II study of administration of continuous erythropoietin receptor activator once every 3 weeks in anemic patients with multiple myeloma receiving chemotherapy. Haematologica. 2007; 92: 493-501
|
|
|
|
|
|
8) Hirsh V, Glaspy J, Mainwaring P, et al. Phase II study of two dose schedules of C. E. R. A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007; 6: 8
|
|
|
|
|
|
9) Stead RB, Lambert J, Wessels D, et al. Evaluation of the safety and pharmacodynamics of Hematide, a novel erythropoietic agent, in a phase 1, double-blind, placebo-controlled, dose-escalation study in healthy volunteers. Blood. 2006; 108: 1830-4
|
|
|
|
|
|
10) Urquilla P, Fong A, Oksanen S, et al. Upregulation of endogenous EPO in healthy subjects by inhibition of hypoxia inducible factor (HIF) prolylhydroxylase. Blood. 2004; 104: 54A-174
|
|
|
|
|
|
11) Gunzler V, Muthukrishnan E, Neumayer HH, et al. FG-2216 increases hemoglobin concentration in anemic patients with chronic kidney disease. Am Soc Nephrol Renal Week. 2005: Abst SA-PO924
|
|
|
|
|
|
12) Akagi S, Ichikawa H, Okada T, et al. The critical role of SRC homology domain 2-containing tyrosine phosphatase-1 in recombinant human erythropoietin hyporesponsive anemia in chronic hemodialysis patients. J Am Soc Nephrol. 2004; 15: 3215-24
|
|
|
|
|